Rheumatoid arthritis

ORIGINAL RESEARCH

Reduced cardiorespiratory fitness is a mediator of excess all-cause mortality in rheumatoid arthritis: the Trøndelag Health Study

Marthe Halsan Liff,1,2 Mari Hoff,3,4 Ulrik Wisloff,5,6 Vibeke Videm

ABSTRACT

Objectives Investigate if low cardiorespiratory fitness (CRF) was associated with and acted as a mediator of excess all-cause mortality rate in persons suffering from rheumatoid arthritis (RA) compared with the general population.

Methods All-cause mortality was analysed using Cox regression modelling in patients with RA (n=348) and controls (n=60 938) who took part in the second (1995–1997) and third (2006–2008) waves of the longitudinal population-based Trøndelag Health Study in Norway. A mediation analysis was performed to investigate if excess relative risk of mortality in RA was mediated by low estimated CRF (eCRF).

Results During the follow-up until 31 December 2018 (mean 19.3 years), the mortality rate among patients with RA (n=127, 36.5%) was higher than among controls (n=12 942, 21.2%) (p<0.001). Among controls and patients with RA, 51% and 26%, respectively, had eCRF above the median for their age and sex (p<0.001). The final Cox model included RA status and eCRF, adjusted for hypertension, body mass index, smoking, cholesterol, diabetes and creatinine. eCRF below median for sex and age category was associated with increased mortality (p<0.001). The total excess relative risk of mortality in patients with RA was 28% (95% CI 2% to 55%, p=0.035), in which RA itself contributed 5% and the direct and indirect contributions of low estimated CRF accounted for 23%.

Conclusions Low eCRF was an important mediator of the increased all-cause mortality rate found in RA. Our data indicate that patients with RA should be given advice to perform physical activity that increases CRF, along with optimised treatment with antirheumatic drugs, from the time of diagnosis.

INTRODUCTION

Rheumatoid arthritis (RA) is a common chronic systematic rheumatic disease affecting joints, tendons, bursae and internal organs including the cardiovascular and respiratory systems. In Norway, RA has a prevalence of 768/100 000 (women 1003/100000, men 513/100 000). The prevalence of RA is quite stable around the world, around 0.5%–1%. Patients with RA often show more unfortunate cardiovascular risk profiles, with higher frequencies of the metabolic syndrome and smoking compared with the general population. In addition, chronic inflammation in RA is regarded as an important contributor to accelerated atherosclerosis leading to increased cardiovascular disease (CVD) that eventually leads to increased rates of premature death in RA. There are indications that improved medical treatment with new biological disease modifying antirheumatic drugs (DMARDs) and targeted synthetic DMARDs in addition to use of conventional DMARDs at higher doses and an earlier disease stage led to reduced inflammation, which in turn has contributed to reduced mortality in patients with RA in short-term studies.
However, robust evidence of improved survival rates in long-term studies in persons with RA is lacking.17

There is strong evidence that the cardiorespiratory fitness (CRF) level affects cardiovascular health, and low CRF is a stronger predictor of adverse cardiovascular outcomes than traditional risk factors.18 CRF is measured as a person’s maximum oxygen uptake (VO\textsubscript{2max}), and is now regarded as a clinical vital sign.18 Exercise training, particularly at high intensities, leads to improved CRF.19 CRF is, therefore, an important modifiable risk factor because it may be improved by increasing relevant physical activity (PA).20

Studies have shown that patients with RA have reduced CRF compared with the healthy population,21–23 whereas PA interventions that improve CRF are associated with increased function and reduction of cardiovascular risk in RA.24 25

The gold-standard method to measure VO\textsubscript{2max} is by cardiopulmonary exercise testing (CPET) either on a treadmill or bicycle ergometer.18 With gradually increasing workload, oxygen expenditure increases until the oxygen ventilation curve flattens as the person reaches physical exhaustion. VO\textsubscript{2max} is the measured level of oxygen ventilation at this point. CPET is a resource-intensive method. Various mathematical models have therefore been developed to estimate VO\textsubscript{2max} (eCRF) without the need for a physical test.18 26–28 One example is the eCRF equation developed by regression analysis with the CPET results from 4260 participants in the third wave of the Trøndelag Health Study (HUNT3) as the dependent variable. The predictors in this model are age, gender, resting heart rate and waist circumference, as well as information about frequency, duration and intensity of PA performed by the participants.26

High eCRF can counteract the increased cardiovascular risk factor clustering caused by long sedentary time,29 and in one study the risk of acute myocardial infarction (MI) in women was inversely associated with the level of eCRF.30 In addition, several studies have shown that eCRF serves as an independent predictor of mortality in the general population.26 31 32 A previous study showed that a 3.5 mL/(min x kg) higher eCRF was associated with a 21% lower HR for CVD mortality in both men and women.31

Despite the strong association between low CRF and mortality found in the general population, evidence is still lacking for importance of the same association in patients with RA. To our knowledge, no population-based studies have analysed CRF level in relation to excess mortality in an RA population. Focus so far has rather been on medication reducing inflammation to prevent excess mortality in RA, and thereby perhaps overlooking the potential additional importance of low CRF as a mediator of increased mortality rates in RA. The hypothesis of this study was that low CRF contributes to the increased mortality in patients with RA compared with the general population. The aims were to investigate if low eCRF was associated with and acted as a mediator of increased all-cause mortality in patients with RA, using data from a large population-based cohort.

**METHODS**

**Participants**

HUNT is a longitudinal population-based health study using an open cohort design. All present inhabitants ≥20 years of age in the northern region of Trøndelag county in Norway are invited to each wave of the study, independent of whether they have previously participated in HUNT. In this study data from the second (HUNT2, 1995–1997, n=65 202, 69.5% of invited) and third (HUNT3, 2006–2008, n=50 787, 54.1% of invited) waves were used.33 Data from the first wave (HUNT1, 1984–1986) could not be included because there was no question regarding RA. All participants in HUNT provided written informed consent.

Based on information in hospital case files, a previous study identified those with a valid RA diagnosis (n=546) out of all participants in HUNT2 and HUNT3 who self-reported RA.2 The standardised 2010 American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria for RA were used during diagnosis validation.34–36 Those with uncertain RA, given an RA diagnosis after HUNT3 and/or having psoriatic arthritis, juvenile inflammatory arthritis, ankylosing spondylitis or other forms of inflammatory arthritis, were excluded. Following exclusion of participants with missing variables for eCRF calculation, 348 patients with RA (235 women and 113 men) and 60 938 controls were included (figure 1).

**Variables**

The following variables and definitions were used: eCRF (mL/(min x kg)) in controls and patients with RA was calculated as previously described and detailed in online supplemental data 1.26–28 Body mass index (BMI) was divided into three categories: <18.5, 18.5–24.9, ≥30.0 kg/m\textsuperscript{2}; hypertension (yes/no): systolic blood pressure ≥140 and/or diastolic blood pressure ≥90 mm Hg and/or self-reported use of antihypertensive medication; previous CVD (yes/no): self-reported stroke and/or angina and/or MI; smoking: self-reported never, previous or present smoking; diabetes (yes/no): self-reported diabetes and/or the use of antidiabetic medication and/or having a non-fasting blood-glucose level >11 mmol/L; creatinine (µmol/L); total cholesterol (mmol/L); seropositive RA: presence of rheumatoid factor and/or anticitrullinated peptide antibody; duration of RA: three categories: <3 years, 4–9 years and ≥210 years.

Data from HUNT2 and HUNT3 were linked with the Norwegian Cause of Death Registry,35 which registers information about all deaths of Norwegian citizens in Norway or abroad.

**Patient and public involvement**

There was no direct patient and public involvement (PPI) involvement in the design of this study. Two PPI
representatives will help select and design material for dissemination of results to their peers and patient groups.

Statistics
Data are given as counts and percentages or mean with SD. P values <0.05 were regarded significant. Statistical analyses were performed using Stata (V.15.1, StataCorp). Normal distribution of continuous variables was evaluated using histograms.

Because HUNT2 and HUNT3 took place approximately 11 years apart, baseline characteristics of the participants could have changed between them. Baseline comparisons for patients with RA and controls were therefore performed separately for HUNT2 and HUNT3, using χ² tests or t-tests.

In brief, the associations of RA and low fitness were analysed using Cox regression. Adjustments for potential confounders were added in steps to better permit evaluation of whether the associations found for RA and low fitness were independent from each other and from the adjustment variables. To investigate the total excess relative risk of mortality in RA and whether it was mediated through low fitness, a Cox regression-based mediation analysis was performed. The details of the analyses are described in the following paragraphs.

All-cause mortality in patients with RA and controls was analysed employing Cox proportional hazard regression modelling in several steps as detailed below. Age was used as the time variable, thereby ensuring that participants were compared with other participants of the same age in all models. This design safeguards against introducing bias due to age differences between patients with RA and controls. The analyses were stratified by sex, and entry was the date for the first participation in HUNT (baseline), that is, either HUNT2 or HUNT3. For those who participated twice, the first observation with complete data for the fully adjusted model (Step 3) was considered the baseline observation; thus those who took part in both HUNT2 and HUNT3 but had missing variables for HUNT2 were included with their baseline defined as HUNT3. For participants in both HUNT2 and HUNT3, relevant variable values were updated in HUNT3. Participants were followed from their baseline until they died, or observation ended on 31 December 2018.

In the main analysis, eCRF was categorised as above or below the median for each participant’s sex and age group (<40 years, 40–59 years, ≥60 years, variable denoted eCRF-dichotomous, using eCRF above the median as reference group) (Figure 2). This was done because fitness is strongly associated with age and significantly higher in men than women. Using eCRF-dichotomous in the main model had two reasons: The Step 3 Cox model was directly comparable to the model used to test eCRF as a mediator of excess mortality in RA (second study aim), for which using more than two eCRF categories was not possible; and because there is some variability in measured CRF compared with eCRF.

The first analytic step (Step 1) consisted of unvariable models for RA status (yes/no) (Step 1a) and...
Table 1  Baseline characteristics*

|                      | HUNT 2 |                      | HUNT 3 |
|----------------------|--------|----------------------|--------|
|                      | RA (n=307) | Controls (n=53 258) | RA versus controls, p value | RA (n=41) | Controls (n=7680) | RA versus controls, p value |
| Female sex, n (%)    | 206 (67) | 27 303 (51)          | <0.001 | 29 (71) | 4426 (58)          | 0.090 |
| Age (years), mean (SD) | 56.3 (12.0) | 47.6 (16.1) | <0.001 | 65.0 (14.2) | 43.7 (17.3) | <0.001 |
| Systolic blood pressure (mm Hg), mean (SD) | 138 (20) | 136 (21) | 0.23 | 142 (20) | 126 (17) | <0.001 |
| Body mass index (kg/m²), mean (SD) | 26.5 (4.1) | 26.2 (4.0) | 0.15 | 29.0 (5.2) | 26.6 (4.6) | 0.041 |
| eCRF-dichotomous     |        |                      |        |        |                      |        |
| Below median, n (%)   | 223 (72.6) | 26 385 (49.5) | <0.001 | 34 (82.9) | 3660 (47.7) | <0.001 |
| Above median, n (%)   | 84 (27.4) | 26 873 (50.5) | 7 (17.1) | 4020 (52.3) |        |        |
| eCRF-tertiles        | <0.001 |                      | <0.001 |        |                      |        |
| Lower tertile, n (%)  | 181 (59.0) | 17 488 (32.8) | 31 (75.6) | 24 49 (31.9) |        |        |
| Middle tertile, n (%) | 69 (22.5) | 17 851 (33.5) | 6 (14.6) | 25 25 (32.9) |        |        |
| Higher tertile, n (%) | 57 (18.6) | 17 919 (33.7) | 4 (9.8) | 27 06 (35.2) |        |        |
| eCRF-continuous (mL/(min x kg)), mean (SD) | 32.4 (9.2) | 40.2 (9.0) | <0.001 | 24.7 (8.7) | 38.5 (9.1) | <0.001 |
| Creatinine (µmol/L), mean (SD) | 85 (13) | 88 (15) | 0.004 | 85 (22) | 82 (15) | 0.13 |
| Total cholesterol (mmol/L), mean (SD) | 6.0 (1.2) | 5.8 (1.2) | 0.014 | 5.6 (1.0) | 5.2 (1.1) | 0.031 |
| Smoking               |        |                      | <0.001 |        |                      | 0.42 |
| Never, n (%)          | 107 (34.9) | 23 955 (45.3) | 18 (43.9) | 41 57 (54.1) |        |        |
| Previous, n (%)       | 107 (34.9) | 12 782 (24.2) | 13 (31.7) | 19 77 (25.7) |        |        |
| Present, n (%)        | 93 (30.3) | 16 119 (30.5) | 10 (24.4) | 15 46 (20.1) |        |        |
| Previous cardiovascular disease, n (%) | 30 (8.8) | 3348 (6.3) | 0.010 | 9 (22) | 395 (5.1) | <0.001 |
| Hypertension, n (%)    | 155 (50.5) | 21 244 (39.9) | <0.001 | 28 (68.3) | 20 15 (26.2) | <0.001 |
| Diabetes, n (%)        | 13 (4.2) | 1402 (2.6) | 0.14 | 3 (7.3) | 280 (3.7) | 0.008 |

Hypertension: systolic blood pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm Hg and/or the use of antihypertensive medication. Previous cardiovascular disease: self-reported stroke and/or angina and/or myocardial infarction. Diabetes: self-reported diabetes and/or the use of antidiabetic medication and/or having a non-fasting blood glucose level >11 mmol/L. eCRF, estimated cardiorespiratory fitness; eCRF-continuous, eCRF as a continuous variable; eCRF-dichotomous, eCRF categorised as above or below the median eCRF for each participant’s sex and age group (<40 years, 40–59 years ≥60 years); eCRF-tertiles, eCRF categorised into higher, middle and lower eCRF tertile for each participant’s sex and age group.

*There were no missing data in patients with RA. Missingness for controls, HUNT2: hypertension 0.03%, smoking 0.08%, body mass index 0.002%, systolic blood pressure 0.01%; HUNT3: systolic blood pressure 0.9%. Comparisons between patients with RA and controls were performed using the χ² test or t-test.

eCRF, estimated cardiorespiratory fitness; HUNT2 and HUNT3, The second and third wave of the longitudinal population-based Trendelag Health study; RA, rheumatoid arthritis.

eCRF-dichotomous (Step 1b) for the relevant age group and sex, respectively. Step 2 was a bivariable model including both RA status and eCRF-dichotomous. Step 3 was a multivariable model including RA status, eCRF-dichotomous and the following adjustment variables: hypertension, BMI, smoking status, total cholesterol, diabetes status and serum creatinine. They were chosen based on published associations with mortality.

Because missingness was very low (table 1), the analysis was performed on complete cases. The proportional hazard assumption was evaluated using Stata’s ph test based on Schoenfeld residuals. For models with violation of the proportional hazard assumption, a corresponding flexible parametric survival model was fitted. If the HRs (mean with 95% CI) were similar, the Cox models were considered acceptable. Linearity of continuous variables was evaluated using Martingale residuals. Models were compared using the Aikaike and Bayesian information criteria (AIC and BIC), where a lower numerical value indicates better fit.

Two sensitivity analyses for the Step 3 (adjusted) model were performed to ascertain whether dichotomisation of eCRF introduced bias. First, categorisation was performed in tertiles for each participant’s sex and age group (variable denoted eCRF-tertiles, using the higher eCRF tertile as reference group). Another sensitivity analysis used eCRF as a continuous variable, denoted as eCRF-continuous. A third sensitivity analysis included adjustment for previous CVD in addition to the adjustments used in the Step 3 model.

To investigate whether an increased mortality rate in RA is mediated by low eCRF, we performed a mediation analysis using the Stata package medWay. In this Cox regression-based analysis, the total effect on mortality of
RESULTS

The baseline characteristics and results from comparisons between patients with RA and controls for participants with baseline in HUNT2 (RA n=307, controls n=53 258) and HUNT3 (RA n=41, controls n=7680) are presented in table 1. BMI was not significantly different between patients with RA and controls for participants with baseline in HUNT2, but the patients with RA with baseline in HUNT3 had significantly higher BMI than controls. Baseline total cholesterol was significantly higher in patients with RA than controls in HUNT2, but not in HUNT3. Higher frequencies of patients with RA were smokers or previous smokers in HUNT2, and had hypertension or previous CVD compared with controls at both baseline time points (table 1).

Out of 348 patients with RA, 247 (71.0%) were seropositive, 93 (26.7%) were seronegative and 8 (2.3%) had unknown serologic status. RA disease duration (<3 years, 4–9 years and ≥10 years) was 27.9%, 49.7% and 19.8%, respectively, and 2.6% lacked information about the duration of RA.

Mean follow-up was 19.3 years (min. 0.2 to max. 23.4 years), during which 13 069 participants died. The all-cause mortality rate was significantly higher among patients with RA (n=127, 56.5%) compared with controls (n=12 942, 21.2%) (p<0.001). Among controls and patients with RA, 51% and 26%, respectively, had baseline eCRF above the median for their age and sex (p<0.001).

Low fitness was strongly associated with mortality in both groups. Of the 127 patients with RA who died, only 4% (n=5) belonged to the high fitness category, in contrast to 8.8% (n=12 942) of the controls (p=0.054). Total time at risk was 1 158 878 person years, that is, 5596 person years for patients with RA and 1 153 281 person-years for controls.

Detailed results from the stepwise Cox regressions and sensitivity analyses are given in table 2.

In the univariable Step 1 Cox analyses, either having RA (p=0.036) (Step 1a) or having eCRF below the median (p<0.001) (Step 1b) were associated with increased mortality. In the bivariable Step 2 model with RA and eCRF-dichotomous, RA status became non-significant (p=0.12) whereas eCRF below the median remained significant (p<0.001). This finding is compatible with the hypothesis that part of the excess mortality risk of RA in the univariable model was in fact explained by the lower eCRF among patients with RA compared with controls. Following adjustment for hypertension, BMI, smoking, total cholesterol, diabetes and creatinine in the Step 3 model, eCRF below the median remained significant (p<0.001) (table 2). The sensitivity analyses showed that results and model fit using eCRF-dichotomous in Step 3 (AIC=213 717.9 and BIC=213 829.7) were comparable to models using eCRF-tertiles (AIC=213 714.4 and BIC=213 835.5) and better than eCRF as a continuous variable (AIC=213 768.0 and BIC=213 879.8). Inclusion of adjustment for previous CVD in the third sensitivity analysis

having RA is calculated as the total excess relative risk of mortality. This excess risk was then split into three paths and the mediator effect of eCRF was calculated fixing eCRF-dichotomous to low, that is, below the sex-specific and age-specific median. In other words, the mediation analysis sought to answer the following question: How much of the association of RA with all-cause mortality was mediated by low fitness (eCRF below median)? (B) Details from results of the mediation analysis. eCRF below median, estimated cardiorespiratory fitness below the sex-specific and age-specific eCRF median using age groups <40 years, 40–59 years or ≥60 years.

| Type of effect | % | 95% CI and p |
|---------------|---|-------------|
| Controlled direct effect of RA on mortality | 5% (-16%, 26%) | p=0.63 |
| Pure indirect effect of RA via eCRF below median when all other variables are adjusted for | 4% (-3%, 5%) | p=0.001 |
| Portion attributable to interaction between RA and eCRF below median when all other variables are adjusted for | 19% (-2%, 41%) | p=0.077 |
| Total excess risk for all-cause mortality | 28% (2%, 55%) | p=0.025 |

Figure 3 Mediation model. (A) The model is based on the Step 3 adjusted Cox regression model and shows how much of the association of RA with all-cause mortality was mediated by low fitness (eCRF below median). (B) Details from results of the mediation analysis. eCRF below median, estimated cardiorespiratory fitness below the sex-specific and age-specific eCRF median using age groups <40 years, 40–59 years or ≥60 years.
had minimal influence on the Cox regression results (Table 2).

Some adjustment variables violated the proportional hazard assumption. However, the coefficients hardly changed when using a flexible parametric survival model instead, so the Cox models were considered acceptable.

Results from the mediation analysis are given in Figure 3. The results showed that having an eCRF below the sex-specific and age-specific median if one suffered from RA acted as a mediator for mortality, which explained 23% (4% plus 19%) of the total increased risk of all-cause mortality of 28%. Thus, the effects of low eCRF exceeded the isolated contribution of RA itself of 5% in this setting. In the sensitivity analysis with additional adjustment for previous CVD, the total increased risk of all-cause mortality was 27%, of which 21% were explained by having an eCRF below the sex-specific and age-specific median. Thus, previous CVD had little influence on the results.

**DISCUSSION**

This study showed that patients with RA had significantly increased long-term all-cause mortality rates compared with controls. When adjusting for other risk factors for mortality, the excess relative risk of 28% was partly associated with the RA disease itself, but the major part, that is, 23%, was mediated by low eCRF combined with the interaction between RA and low eCRF. The contribution of the interaction to the total increased relative risk of mortality was not significant (p=0.077), but this is likely a false-negative result due to low power because very few of the patients with RA who died had eCRF above the median. However, residual confounding due to missing adjustment variables cannot be excluded. Because eCRF is modifiable, results from this study are particularly interesting as increasing PA that leads to improved CRF may translate to reduced mortality rates in patients with RA.

### Table 2 Results from Cox regression analyses for all-cause mortality

| Step | Variable | HR (95% CI) | P value |
|------|----------|-------------|---------|
| Step 1a | RA (univariable) | Control: reference | RA: 1.21 (1.01 to 1.45) | 0.036 |
| Step 1b | eCRF-dichotomous (univariable) | eCRF above median: reference | eCRF below median: 1.19 (1.14 to 1.23) | <0.001 |
| Step 2 | RA and eCRF-dichotomous (bivariable) | Control: reference | RA: 1.15 (0.96 to 1.37) | 0.12 |
|       |          | eCRF above median: reference | eCRF below median: 1.19 (1.14 to 1.23) | <0.001 |
| Step 3 | RA and eCRF-dichotomous, adjusted for hypertension, BMI, smoking, total cholesterol, diabetes and creatinine | Control: reference | RA: 1.10 (0.93 to 1.32) | 0.27 |
|       |          | eCRF above median: reference | eCRF below median: 1.18 (1.13 to 1.23) | <0.001 |
| Sensitivity analysis 1 | RA and eCRF-tertiles, adjusted for hypertension, BMI, smoking, total cholesterol, diabetes and creatinine | Control: reference | RA: 1.09 (0.91 to 1.30) | 0.34 |
|       |          | eCRF higher tertile: reference | eCRF middle tertile: 1.12 (1.07 to 1.17) | <0.001 |
|       |          | eCRF lower tertile: 1.24 (1.18 to 1.31) | <0.001 |
| Sensitivity analysis 2 | RA and eCRF-continuous, adjusted for hypertension, BMI, smoking, total cholesterol, diabetes and creatinine | Control: reference | RA: 1.10 (0.93 to 1.32) | 0.25 |
|       |          | eCRF-continuous: 0.99 (0.989 to 0.997) | 0.001 |
| Sensitivity analysis 3 | RA and eCRF-dichotomous, adjusted for hypertension, BMI, smoking, total cholesterol, diabetes, creatinine and previous cardiovascular disease | Control: reference | RA: 1.08 (0.91 to 1.29) | 0.39 |
|       |          | eCRF above median: reference | eCRF below median: 1.18 (1.13 to 1.23) | <0.001 |

Hypertension: systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or use of antihypertensive medication.
Previous cardiovascular disease: self-reported stroke and/or angina and/or myocardial infarction. Diabetes: self-reported diabetes and/or use of antidiabetic medication and/or having a non-fasting blood-glucose level >11 mmol/L.
BMI, body mass index; eCRF, estimated cardiorespiratory fitness; eCRF-continuous, eCRF as a continuous variable; eCRF-dichotomous, eCRF categorised as above or below the median eCRF for each participant’s sex and age group (<40 years, 40-59 years, >60 years); eCRF-tertiles, eCRF categorised into higher, middle and lower eCRF tertile for each participant’s sex and age group; RA, rheumatoid arthritis.
In the following years, new treatment strategies like ‘Treat to target’ with new drugs have been in focus. An unintended consequence might be that registration of inflammation levels and radiographic changes may have been performed almost at the expense of other outcomes like CRF and other measures of physical function.

New and better drugs increase quality of life, reduce inflammation and radiographic change, and thereby help patients with RA exercise; however, drugs alone do not increase CRF. There is no doubt that higher CRF is associated with longer survival in the general population, and the present study gives evidence that this also applies to patients with RA. Thus, increasing fitness may be an important tool for reduction of preterm mortality, counteracting the increased age-related decline in eCRF described in RA. In addition to early medical treatment, encouragement and information about suitable PA and exercise training, in particular at high intensity, should therefore be an obligatory part of RA treatment strategies from the time of diagnosis.

An increasing focus on PA is reflected in the latest 2017 EULAR recommendations for PA in arthritis. They state that arthritis patients should follow the same recommendations for PA as the general population and that PA in RA is safe. Perhaps because of lacking evidence, The EULAR recommendations for prevention of CVD recommend PA because it might reduce inflammation and prevent CVD, but CRF and related terms are not mentioned. The present finding that low eCRF clearly acts as a mediator of excess mortality in RA contributes to the evidence supporting improvement of CRF as an important tool for preventive care also in patients with RA.

Some studies have indicated that the mortality gap between patients with RA and the general population is narrowing. However, comparison of RA populations diagnosed in different time periods using different criteria and various follow-up strategies may result in a false impression of a narrowing mortality gap. Cigarette smoking is associated with earlier debut of seropositive and more severe RA and is a well-known risk factor for atherosclerosis and increased mortality rates. One may ask whether the overall observed reduction of smoking in most industrialised countries has a more positive effect in patients with RA compared with the general population and is possibly contributing to narrowing of the mortality gap. However, low eCRF remained a strong risk factor for mortality in our study after adjustment for smoking and other variables associated with mortality and CVD.

Access to lifestyle-related and other relevant adjustment variables in HUNT, and the long follow-up should be regarded as strengths of our study. The low number of patients with RA may represent a weakness, but the very large population-based control group reduces selection bias and thereby improves the validity of the results.

Another strength of the present study is that RA diagnoses were confirmed from medical records and not based on self-report or diagnostic codes in various registries. Given that many of our study participants were diagnosed with RA several years ago and that their eCRF was not recently updated, it may be argued that the findings are no longer relevant. A previous study from our group found that patients with RA who performed CPET in 2017 were deconditioned compared with the healthy population and use of various conventional and biological DMARDs was not associated with CRF. The results are therefore probably relevant for today’s RA population as well, even if there have been large changes in medication and treatment strategies.

Using eCRF instead of the measured CRF from CPET may be regarded as a limitation of this study. However, using CPET may introduce selection bias, as those more used to PA may be more motivated for participation. Using eCRF calculated from other data makes it possible to include a wider range of participants. Furthermore, performing CPET in such a large population-based study would have been practically and economically impossible.

Because HUNT has an open cohort design, participants in our study had different baselines. This permitted inclusion of more participants and thereby provided higher statistical power, as well as the possibility of updating the data for those who participated twice. However, we cannot exclude that studying participants having different baselines could have influenced the results.

In conclusion, this study showed that low CRF was an important mediator of the increased mortality found in patients with RA. In addition to optimal medical treatment, focus on improvement and follow-up of CRF should be an integral part of standard treatment of RA already from the time of diagnosis.

Acknowledgements The HUNT Study (Trøndelag Health Study) is a collaboration between the HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology), the Nord-Trøndelag

Author affiliations
1Clinic of Orthopaedics, Rheumatology and Dermatology, St Olavs University Hospital, Trondheim, Norway
2Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, Trondheim, Norway
3Department of Neuromedicine and Movement Science, NTNU - Norwegian University of Science and Technology, Trondheim, Norway
4Department of Rheumatology, St Olavs University Hospital, Trondheim, Norway
5School of Human Movement & Nutrition Sciences, The University of Queensland, Saint Lucia, Queensland, Australia
6Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
Combe B, Landewe R, Dahaïl CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. *Ann Rheum Dis* 2017;76:948–59.  
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 2015;74:480–9.  
Provan SA, Lillegaard S, Sexton J, et al. Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched-case–cohort study. *Rheumatology* 2020;59:505–12.  
Lacaille D, Avina-Zubieta JA, Sayre EC, et al. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population - closing the mortality gap. *Ann Rheum Dis* 2017:76:1057–63.  
Holmquist M, Ljung L, Askling J. Mortality following new-onset rheumatoid arthritis: has modern rheumatology had an impact? *Ann Rheum Dis* 2018;77:85–91.  
Nass R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. *Circulation* 2016;134: e655–99.  
Weston KS, Wielofòt U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br J Sports Med 2014;48:1227–34.  
Aspenes ST, Nauman J, Nilsen TL, et al. Physical activity as a long-term predictor of peak oxygen uptake: the HUNT study. *Med Sci Sports Exerc* 2011;43:1675–9.  
Lift MH, Hoff M, Freme T. Cardiorespiratory fitness in patients with rheumatoid arthritis is associated with the patient global assessment but not with objective measurements of disease activity. *RMD Open* 2019;5:e000912.  
Munsterman T, Takken T, Wittink H. Are persons with rheumatoid arthritis deconditioned? A review of physical activity and aerobic capacity. BMC Musculoskelet Disord 2012;13:202.  
Metios GS, Koutedakis Y, Veldhuijzen van Zanten JJS, et al. Cardiorespiratory fitness levels and their association with cardiovascular profile in patients with rheumatoid arthritis: a cross-sectional study. *Rheumatology* 2015;54:kw035–20.  
Metios GS, Lemmey A. Exercise as medicine in rheumatoid arthritis: effects on function, body composition, and cardiovascular disease risk. *J Clin Exerc Physiol* 2015;4:14–22.  
Slavopoulos-Kaligoulo A, Metios GS, Veldhuijzen van Zanten JJS, et al. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. *Ann Rheum Dis* 2013;72:1819–25.  
Nes BM, Janszky I, Vatten LJ, et al. Estimating V-O2peak from a nonexercise prediction model: the HUNT study, Norway. *Med Sci Sports Exerc* 2011;43:2024–30.  
Lift MH, Hoff M, Freme T, et al. An estimation model for cardiorespiratory fitness in adults with rheumatoid arthritis. *Med Sci Sports Exerc* 2020;52:1248–55.  
Nauman J, Nes BM, Løvås C, et al. Prediction of cardiovascular mortality by estimated cardiorespiratory fitness independent of traditional risk factors: the HUNT study. *Mayo Clin Proc* 2017;92:218–27.  
Nauman J, Stensvold D, Coombes JS, et al. Cardiorespiratory fitness, sedentary time, and cardiovascular risk factor clustering. *Med Sci Sports Exerc* 2016;48:625–32.  
Shigeld R, Dalen H, Sui X, et al. Cardiorespiratory fitness and the risk of first acute myocardial infarction: the HUNT study. *J Am Heart Assoc* 2019;8:e010923.  
Nes BM, Vatten LJ, Nauman J, et al. A simple nonexercise model of cardiorespiratory fitness predicts long-term mortality. *Med Sci Sports Exerc* 2014;46:1159–65.  
Stamatakis E, Hamer M, O’Donovan G, et al. A non-exercise testing method for estimating cardiorespiratory fitness: associations with all-cause and cardiovascular mortality in a pooled analysis of eight population-based cohorts. *Eur Heart J* 2013;34:750–8.  
Krokstad S, Langhammer A, Hveem K, et al. Cohort profile: the HUNT study, Norway. *Int J Epidemiol* 2013;42:968–77.  
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;62:690–91.  
Lif MH, et al. *RMD Open* 2021;7:a001545. doi:10.1136/rmdopen-2020-001545
36 Discacciati A, Bellavia A, Lee JJ, et al. Med4way: a Stata command to investigate mediating and interactive mechanisms using the four-way effect decomposition. *Int J Epidemiol* 2019;48:15–20.
37 Sokka T, Häkkinen A. Poor physical fitness and performance as predictors of mortality in normal populations and patients with rheumatic and other diseases. *Clin Exp Rheumatol* 2008;26:S14–20.
38 Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. *Best Pract Res Clin Rheumatol* 2003;17:753–81.
39 Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. *Best Pract Res Clin Rheumatol* 2007;21:601–28.
40 Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. *Ann Intern Med* 1994;120:26–34.
41 Pincus T, Summey JA, Soraci SA, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health assessment questionnaire. *Arthritis Rheum* 1983;26:1346–53.
42 Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. *Ann Rheum Dis* 2011;70:812–7.
43 Kraus WE, Powell KE, Haskell WL, et al. Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. *Med Sci Sports Exerc* 2019;51:1270–81.
44 Liff MH, Hoff M, Wisløff U, et al. Faster age-related decline in cardiorespiratory fitness in rheumatoid arthritis patients: an observational study in the Trøndelag health study. *Rheumatol Int* 2021;41:369–79.
45 Rausch Osthoff A-K, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. *Ann Rheum Dis* 2018;77:1251–60.
46 Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc* 2011;43:1334–59.
47 Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis* 2017;76:17–28.
48 Ishikawa Y, Terao C. The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review. *Cells* 2020;9:475. doi:10.3390/cells90200475